Since the introduction of penicillin in the early twentieth century, antimicrobial treatments have been utilized not only in human medicine but also in veterinary care – initially to ward off diseases, prevent post-surgery infections, and treat sick farm animals.Global food production... has intensified over the past 50 years due to economic expansion and popu-lation growth. The use of antimicrobials in agriculture – in livestock, fish farming, and even on crops – has grown as well. Antimicrobials are not only used as medicines, but are sometimes also added in low concentrations to animal feed as a way of stimulating growth.
more
Despite the existence of criminal law, which is an important aspect of anti-FGM policies and programmes, there is not much research on the effects of cross-border practices that invalidate the law as a deterrent. Much remains unknown about the practice of cross-border FGM, specifically about gaps in... existing policy and legislation for managing cross-border FGM, as well as whether the existing interventions in the cross-border areas are sufficiently targeted to facilitate changes in social norms
more
Operational Guidelines and Field Manual on Human Rights Protection in Situations of Natural Disaster
A guide to facilitating community-managed disaster risk reduction in the Horn of Africa.
This manual describes how to help communities implement disaster risk reduction activities. It was written for development workers and community-based organizations in the Horn of Africa, but practitioners can ...use it to implement activities around the world
more
Reporting period: January 2008-December 2010
Accessed: 29.09.2019
Project Paper to provide an additional grant for: Human Development Systems Strengthening Project (HDSSP)(P145965, H9360)
PLoS ONE 15(1): e0228135.
The introduction of “Treat All” (TA) has been promoted to increase the effectiveness of HIV/AIDS treatment by having patients initiate antiretroviral therapy at an earlier stage of their illness. The impact of introducing TA on the unit cost of treatment has been less ...clear. The following study evaluated how costs changed after Namibia’s introduction of TA in April 2017.
more
The Consensus Statement on c-IPTp is a publication by the RBM Partnership to End Malaria. It focuses on community-based intermittent preventive treatment in pregnancy (c-IPTp), aiming to enhance malaria prevention among pregnant women through community-level interventions. The statement offers po...licies, recommendations, and joint statements to guide the implementation of c-IPTp strategies. The document is available for download in English, French, and Portuguese.
more
Challenges and Opportunities. This report presents a comprehensive assessment of the education and labor markets for nurses in the ECSA region. It documents the main challenges to train and deploy nurses and discusses opportunities for government and private sector employers to overcome these chall...enges. The report provides empirical evidence to support the expansion of nursing education within the region with a focus on private sector engagement, effective labor market regulation, and regional collaboration. A regional focus for investment may be necessary to create enough potential deals, reduce individual country and regulatory risks, encourage good private institutions to move across borders within the region, and seek to create regional standards for regulation.
more
This document by Medicines for Malaria Venture (MMV) highlights the significant burden of malaria on children worldwide, emphasizing the need for effective prevention, diagnosis, and treatment strategies. It reviews current challenges and progress in combating pediatric malaria, advocating for conti...nued research and investment to reduce malaria-related morbidity and mortality in children, especially in high-burden regions.
more
Clinical Pharmacology: Advances and Applications, 2025:17 29–47
Two malaria vaccines are currently WHO prequalified and recommended1 for use to prevent
P. falciparum malaria in young children, the RTS,S/AS01 vaccine, currently manufactured by
GlaxoSmithKline (GSK), and the R21/Matrix-M vaccine, manufactured by Serum Institute of India
Pvt (SII)